{"groups":[{"description":"Participants with chronic kidney disease and a diagnosis of secondary hyperparathyroidism, and who were not yet on dialysis received paricalcitol injection or capsules, on an on-label basis in an everyday setting. Participants were observed for 12 months.","id":"FG000","title":"Paricalcitol Pre-dialysis Group"},{"description":"Participants with chronic kidney disease and a diagnosis of secondary hyperparathyroidism, and on dialysis received paricalcitol injection or capsules, on an on-label basis in an everyday setting. Participants were observed for 12 months.","id":"FG001","title":"Paricalcitol Dialysis Group"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"121"},{"groupId":"FG001","numSubjects":"638"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"61"},{"groupId":"FG001","numSubjects":"527"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"60"},{"groupId":"FG001","numSubjects":"111"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"761 participants were enrolled in the study, but two participants lacked information necessary for assignment to one of the analysis groups (pre-dialysis or dialysis). Hence, analysis was conducted with 759 participants."}